Gossamer Bio is trading 5.6% lower at $9.21, with biotech sector weakness providing context for the decline.
- The biotech sector ETF was down 2.01% during the regular session.
- Search results showed no new company-specific announcement explaining the move.
- Chardan’s Buy initiation and $160 target were reported October 13, alongside positive comments on seralutinib; that prior bullish coverage does not explain today’s decline.